

# Protein Kinase 2010: Signalling Success

4<sup>th</sup> SCI-RSC Symposium on kinase inhibitor design

Wednesday 20 October 2010

The Nucleus, Chesterford Research Park, Little Chesterford, UK

Organised by SCI's Fine Chemicals Group and the  
RSC Biological and Medicinal Chemistry Sector

TIME	TITLE	SPEAKER	AFFILIATION
9:30-9:55	Registration and refreshments		
9:55-10:00	Welcome and opening remarks		
10:00-10:45	Plenary lecture: Protein Kinase Inhibitors by Fragment-Based Approaches: Optimization of post-Lipinski parameters	Gerhard Müller	Proteros
10:45-11:20	The discovery of an orally available CDK inhibitor through fragment based drug design	Valerio Berdini	Astex
11:20-11:55	Phthalazinone pyrazoles as potent, selective and orally bioavailable inhibitors of Aurora-A Kinase	Fred Brookfield	Evotec
11:55-12:30	Chromenone based inhibitors of DNA-PK	Ray Finlay	AstraZeneca
12:30-14:00	Lunch break and poster session		
14:00-14:45	Plenary lecture: Selective targeting of phosphorylation signalling networks	Stefan Knapp	SGC
14:45-15:20	Discovery of a novel ChK inhibitor	Karen Williams	Argenta
15:20-15:55	MAPKAPK-5 inhibitors for the treatment of rheumatoid arthritis	Mark Chambers	BioFocus
15:55-16:20	Break for refreshments		
16:20-16:55	Discovery of a potent and selective, orally efficacious IKK2 Inhibitor for the treatment of rheumatoid arthritis	John Liddle	GSK
16:55-17:30	Inhaled p38 inhibitors for the treatment of COPD	David Millan	Pfizer
17:30	Closing remarks		